Ind-Swift Laboratories Ltd. — Capital/Financing Update 2024

Aug 30, 2024

==> picture [425 x 83] intentionally omitted <==

Ref: ISLL:CH:2024

Date: 30[th] August, 2024

The President	The Vice President,
Corporate Relationship Department	Listing Compliance Department,
BSE Limited	National Stock Exchange of India Limited,
Phiroze Jeejeebhoy Towers,	Exchange Plaza, 5th Floor
25th Floor, Dalal Street,	Plot No. C/2, G-Block,
Mumbai 400 001	Bandra Kurla Complex, Bandra (E),
	Mumbai 400 051

BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB

Subject : Allotment of 2,60,00,000 Fully Convertible Warrants at an issue price of Rs. 121/on preferential basis.

Ref: Outcome of the meeting of the Preferential Issue Committee of Board of Directors of Ind-Swift Laboratories Limited (“the Company”) in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

Dear Sir/ Madam,

Pursuant to the approval of shareholders of the Company obtained in the EGM held on 22[nd] July, 2024 by way of special resolution, ‘In-Principle approval’ obtained from the stock exchanges i.e., BSE Limited and National Stock Exchange of India Limited and in accordance with the provisions of Regulation 30 of the Listing Regulations, we wish to inform your good office that the Preferential Issue Committee of the Board of Directors of the Company, at its meeting held today i.e., August 30, 2024, has inter alia, considered and approved the allotment of 2,60,00,000 (Two Crores and Sixty Lakh) Fully Convertible Warrants (“Warrants”) , for cash at an issue price of Rs. 121/- (Rupees One Hundred and Twenty One Only) per warrant, convertible at an option of Warrant holder(s) in one or more tranches, within 18 (Eighteen) months from its allotment date into an equivalent number of fully paid-up equity shares of the face value of Rs.10 each/- by way of preferential allotment to below mentioned allottees in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, after receipt of stipulated amount i.e., 25% of the Issue Price as subscription amount:-

==> picture [418 x 103] intentionally omitted <==

----- Start of picture text -----

Sr. No. Name of the Allottees Category No. of Warrants allotted
1. Essix Biosciences Limited Promoter & 80,00,000
Promoter Group
2. HCP Investments 75,00,000
3. Saral Incorporated VCC Sub Fund 65,00,000
Non-Promoter
1
4. Zeal Global Opportunities Fund 40,00,000
Total 2,60,00,000
----- End of picture text -----

The warrants allotted on the preferential basis shall be locked in for specified period in accordance with the provisions of Chapter V of the provisions of SEBI (ICDR) Regulations, 2018.

Digitally signed Pardeep by Pardeep Verma Verma Date: 2024.08.30 18:30:44 +05'30'

==> picture [425 x 83] intentionally omitted <==

The meeting of the Preferential Issue Committee commenced at 05:45 P.M. and concluded at 06:15 P.M.

You are requested to kindly take note of the same.

Thanking You

For IND-SWIFT LABORATORIES LTD.

Pardeep Digitally signed by Pardeep Verma Verma Date: 2024.08.30 18:31:12 +05'30' PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY

==> picture [425 x 40] intentionally omitted <==